Changes in Beneficial Ownership · 4
Dyne Therapeutics, Inc.
DYNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-02
- Issuer
- Dyne Therapeutics, Inc.
- Issuer CIK
- 0001818794
- Trading symbol
- DYN
Reporting owner 1
- Name
- Posner Brian S
- Reporting owner CIK
- 0001372455
- Relationship
- Director
- Address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-02 | P · Form 4 | 2,500 | A | 16.00 | 27,000 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Signature 1
- Signed
- /s/ Ron Caponigro, Attorney-in-Fact
- Date
- 2026-10-06
Company context
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.